← All trials
NCT06993870
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 16, 2025
- Primary completion
- Mar 1, 2026
- Completion date
- Jun 28, 2027
- First posted
- May 29, 2025
- Last posted
- Jul 11, 2025
- Enrollment
- 60
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.